// AST – IMS - [DMinute_ROS]

Intrepid Capital Management Boosted Its Amerisourcebergen Com (ABC) Holding; Godsey & Gibb Associates Has Trimmed Its Pfizer (PFE) Stake

AmerisourceBergen Corporation (NYSE:ABC) Logo

Godsey & Gibb Associates decreased Pfizer Inc (PFE) stake by 12.14% reported in 2018Q2 SEC filing. Godsey & Gibb Associates sold 48,363 shares as Pfizer Inc (PFE)’s stock rose 17.09%. The Godsey & Gibb Associates holds 350,081 shares with $12.70M value, down from 398,444 last quarter. Pfizer Inc now has $260.93 billion valuation. The stock decreased 1.85% or $0.85 during the last trading session, reaching $45.14. About 27.23M shares traded or 20.77% up from the average. Pfizer Inc. (NYSE:PFE) has risen 19.90% since December 5, 2017 and is uptrending. It has outperformed by 4.28% the S&P500. Some Historical PFE News: 06/03/2018 – GLYCOMIMETICS: RIVIPANSEL PHASE 3 TRIAL END ON TRACK FOR 2H’18; 03/04/2018 – PFIZER, ALLOGENE THERAPEUTICS ENTER ASSET CONTRIBUTION PACT; 19/03/2018 – BioDuro Collaboration with Pfizer Inc. Leads to Creation of a Shelf-Stable Fluorosulfation Reagent; 07/05/2018 – Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Newly Diagnosed Multiple Myeloma; 05/04/2018 – Barclays upgrades Merck, downgrades competitor Pfizer; 16/05/2018 – Pfizer Oncology to Showcase Clinical Advances from its Growing Portfolio and Research Pipeline at ASCO; 20/04/2018 – Pfizer Bond Trading 2x Average; Clients Net Buyers; 06/04/2018 – North American Over the Counter Drugs Market 2018-2023 Forecast to Reach $55.6 Billion with Sanofi, GlaxoSmithKline, Pfizer and Bayer Dominating – ResearchAndMarkets.com; 10/04/2018 – Tuberous Sclerosis Alliance salutes FDA approval of Afinitor® DISPERZ (everolimus) as the first adjunctive treatment approved; 23/03/2018 – Pfizer’s quit-smoking Chantix fails study in adolescent smokers

Intrepid Capital Management Inc increased Amerisourcebergen Corp Com (ABC) stake by 7.14% reported in 2018Q2 SEC filing. Intrepid Capital Management Inc acquired 10,495 shares as Amerisourcebergen Corp Com (ABC)’s stock declined 6.01%. The Intrepid Capital Management Inc holds 157,485 shares with $13.43M value, up from 146,990 last quarter. Amerisourcebergen Corp Com now has $18.57 billion valuation. The stock decreased 1.58% or $1.41 during the last trading session, reaching $87.61. About 2.10 million shares traded or 53.19% up from the average. AmerisourceBergen Corporation (NYSE:ABC) has risen 1.56% since December 5, 2017 and is uptrending. It has underperformed by 14.06% the S&P500. Some Historical ABC News: 02/05/2018 – AmerisourceBergen 2Q Adj EPS $1.94; 09/03/2018 – The Moyer Foundation Receives Grant from the AmerisourceBergen Foundation to Launch New Community Program for Children Living; 02/05/2018 – AMERISOURCEBERGEN 2Q ADJ EPS $1.94, EST. $1.82; 23/04/2018 – US Acute Care Solutions Names Dr. Dominic J. Bagnoli Executive Chairman and James Frary Chief Executive Officer; 15/05/2018 – Vulcan Adds Facebook, Exits Booking, Cuts AmerisourceBergen: 13F; 26/04/2018 – AmerisourceBergen Foundation Creates Opioid Resource Grant Program; 25/05/2018 – AmerisourceBergen Presenting at Goldman Sachs Conference Jun 12; 02/05/2018 – AmerisourceBergen Sees FY18 Adjusted Operating Income Growth to Be Flat; 15/05/2018 – U.S. state lawsuits against Purdue Pharma over opioid epidemic mount; 21/04/2018 – DJ AmerisourceBergen Corporation, Inst Holders, 1Q 2018 (ABC)

Among 3 analysts covering AmerisourceBergen (NYSE:ABC), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. AmerisourceBergen had 4 analyst reports since July 3, 2018 according to SRatingsIntel. The firm has “Neutral” rating by Robert W. Baird given on Friday, July 20. The firm has “Equal-Weight” rating given on Tuesday, July 3 by Morgan Stanley. As per Monday, December 3, the company rating was maintained by Morgan Stanley. As per Friday, November 30, the company rating was maintained by RBC Capital Markets.

More notable recent AmerisourceBergen Corporation (NYSE:ABC) news were published by: Seekingalpha.com which released: “AmerisourceBergen soft revenue forecast may pressure drug distributors – Seeking Alpha” on November 06, 2018, also Seekingalpha.com with their article: “ABC’s PharMEDium working on remedial measures, restart uncertain – Seeking Alpha” published on November 06, 2018, Seekingalpha.com published: “AmerisourceBergen declares $0.40 dividend – Seeking Alpha” on November 06, 2018. More interesting news about AmerisourceBergen Corporation (NYSE:ABC) were released by: Nasdaq.com and their article: “Recent Analysis Shows NetApp, Williams-Sonoma, DENTSPLY SIRONA, Applied Materials, Alleghany, and AmerisourceBergen Market Influences — Renewed Outlook, Key Drivers of Growth – Nasdaq” published on December 04, 2018 as well as Seekingalpha.com‘s news article titled: “AmerisourceBergen (ABC) Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 06, 2018.

Investors sentiment decreased to 0.78 in Q2 2018. Its down 0.11, from 0.89 in 2018Q1. It is negative, as 52 investors sold PFE shares while 754 reduced holdings. 112 funds opened positions while 518 raised stakes. 3.98 billion shares or 0.73% less from 4.01 billion shares in 2018Q1 were reported. Roundview Limited Co invested 0.53% of its portfolio in Pfizer Inc. (NYSE:PFE). Ancora Advsr Limited Liability has 290,852 shares. Fuller And Thaler Asset Mgmt Inc accumulated 0.01% or 32,000 shares. Bluefin Trading Ltd Co holds 0.02% or 9,100 shares. Blue Fin Cap reported 0.88% of its portfolio in Pfizer Inc. (NYSE:PFE). Driehaus Cap Lc reported 7,772 shares. Bluecrest Capital Management Limited holds 0.41% or 435,609 shares. Mackenzie owns 4.69M shares. Bremer National Association invested in 53,538 shares. Chatham Group owns 31,185 shares. Brave Asset Management Incorporated invested in 60,465 shares. Bokf Na reported 554,963 shares stake. 315,102 are held by Hennessy Advisors. Delaware-based Reliance Tru Of Delaware has invested 0.52% in Pfizer Inc. (NYSE:PFE). Massachusetts-based S&Co has invested 0.14% in Pfizer Inc. (NYSE:PFE).

Among 7 analysts covering Pfizer (NYSE:PFE), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. Pfizer had 9 analyst reports since June 7, 2018 according to SRatingsIntel. The firm earned “Equal-Weight” rating on Thursday, August 23 by Barclays Capital. On Wednesday, August 1 the stock rating was maintained by BMO Capital Markets with “Outperform”. The company was downgraded on Thursday, November 1 by BMO Capital Markets. The firm has “Buy” rating by Bank of America given on Wednesday, August 1. Credit Suisse maintained the shares of PFE in report on Wednesday, August 1 with “Neutral” rating. Credit Suisse maintained the stock with “Neutral” rating in Wednesday, October 31 report. Citigroup maintained Pfizer Inc. (NYSE:PFE) on Tuesday, November 6 with “Sell” rating. Morgan Stanley maintained Pfizer Inc. (NYSE:PFE) on Thursday, August 23 with “Overweight” rating. Cantor Fitzgerald initiated the shares of PFE in report on Thursday, June 7 with “Buy” rating.

Since June 6, 2018, it had 0 buys, and 2 insider sales for $1.92 million activity. OLSON LAURIE J sold $692,582 worth of Pfizer Inc. (NYSE:PFE) on Wednesday, June 6. SUSMAN SALLY had sold 40,381 shares worth $1.50M on Friday, July 20.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “Pfizer’s Rituxan biosimilar successful in late-stage study; shares up 1% premarket – Seeking Alpha” on December 03, 2018, also Seekingalpha.com with their article: “Pfizer Receives FDA Approval For AML Drug – Seeking Alpha” published on November 27, 2018, Investorplace.com published: “Monday’s Vital Data: Pfizer, Goldman Sachs and Caterpillar – Investorplace.com” on December 03, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Investorplace.com and their article: “Pfizer Stock Has Multiple Positive Catalysts – Investorplace.com” published on November 21, 2018 as well as Fool.com‘s news article titled: “3 Big Pharma Stocks Hitting 52-Week Highs — Are They Buys? – Motley Fool” with publication date: December 04, 2018.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on January, 29. They expect $0.64 earnings per share, up 3.23% or $0.02 from last year’s $0.62 per share. PFE’s profit will be $3.70 billion for 17.63 P/E if the $0.64 EPS becomes a reality. After $0.78 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -17.95% negative EPS growth.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.